Zenith Drugs IPO Allotment Status Online

The Zenith Drugs IPO allotment status will be available on February 23, 2024, as per the timeline provided in the red-herring prospectus.

Below are the steps to check Zenith Drugs IPO allotment status online:

• Visit the Zenith Drugs IPO allotment status page.
• Click on the green Zenith Drugs IPO Allotment Status.
• Enter either PAN number, Application Number or DP Client ID of the demat account to check the Zenith Drugs IPO allotment status.
• Click Search.

Note: The disabled button shows that the allotment is not yet available online.

The allotment result looks like as below:

• PAN No.: AHMLK1898J
• Application No.: RL041213805307
• Name: Mr. Rajveer Singh
• Shares Applied: 40
• Shares Allotted: 40

The expected listing price of Zenith Drugs IPO depends on many factors including demand, nature of the business, market environment and state of the economy. The Zenith Drugs IPO grey market premium gives some hint but the actual listing price is difficult to guess.

Zenith Drugs IPO allotment status is expected on February 23, 2024. Click the green button Zenith Drugs IPO Allotment Status above to check the allotment. Note the button remains to disable until the allotment is available online.

If Zenith Drugs IPO oversubscribed in the retail category, the Zenith Drugs IPO shares will be distributed on a proportionate basis to Retail Individual Investors (RII). Each retail investor will get a minimum of 1 lot subject to the availability of shares in the retail portion. If enough shares are not available, a lottery is drawn to choose the investors.

The Zenith Drugs IPO shares will get listed on Tuesday, February 27, 2024. The equity share of Zenith Drugs Limited will list on NSE SME.

The reason you didn't get the Zenith Drugs IPO could be:

• IPO become oversubscribed and allotment process is completed through a lottery
• The IPO application got rejected due to mismatch/incomplete information
• The issue price is higher than the bid price. (Always apply on cut-off price).